Galecto Commences Underwritten Public Offering of Common and Preferred Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2026
0mins
Should l Buy GLTO?
Galecto announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, Series C non-voting convertible preferred stock. All of the securities are being offered by Galecto. Galecto intends to use the proceeds from the proposed underwritten public offering of its shares of common stock and Series C preferred stock, together with its cash and cash equivalents, for preclinical studies, clinical trials, and manufacturing in support of its antibody programs, as well as for additional research and development activities, working capital, and general corporate purposes. Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the offering.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GLTO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GLTO
Wall Street analysts forecast GLTO stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 29.780
Low
36.00
Averages
41.00
High
46.00
Current: 29.780
Low
36.00
Averages
41.00
High
46.00
About GLTO
Galecto, Inc. is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. It is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Galecto Prices Public Offering at $19.00 per Share, Expected to Raise $275M
- Public Offering Pricing: Galecto has priced its underwritten public offering at $19.00 per share for approximately 14.47 million shares, expecting to raise about $275 million, which will support its R&D and operations, although the stock traded 3.8% lower in after-hours trading, indicating investor caution regarding the offering.
- Underwriters' Option: The underwriters have a 30-day option to purchase an additional 2.17 million shares, providing flexibility that could enhance the company's financial position and strengthen its competitive edge in the biopharmaceutical sector.
- Offering Closure Date: The offering is expected to close on or about February 12, 2026, allowing the company ample time to optimize its funding allocation plans to ensure effective use of the proceeds and smooth project advancement.
- Executive Appointments: Galecto has appointed former Blueprint Medicines executives as COO and CMO, which may bring new strategic insights and management experience to the company, further driving its business development.
See More
Galecto Appoints New Executives to Advance DMR-001 Clinical Trials
- Executive Appointments: Galecto has appointed Sherwin Sattarzadeh as COO and Becker Hewes as CMO, both from Blueprint Medicines, leveraging their 20+ years of drug development experience to drive DMR-001 into clinical trials.
- Clinical Advancement: DMR-001, a monoclonal antibody targeting mutant calreticulin, is on track for IND submission in mid-2026, with plans for first-in-human dosing via subcutaneous administration, marking a significant step in blood cancer treatment.
- Financial Position: The company's cash balance, including $285 million raised in a PIPE in November 2025, provides a financial runway into 2029 to support multiple data milestones, including Phase 1 clinical proof-of-concept data for DMR-001 expected in 2027.
- Incentive Plan: The appointments of Sattarzadeh and Hewes come with stock incentive grants of 190,376 and 264,629 restricted stock units respectively, reflecting the company's commitment to its executive team and confidence in future growth.
See More
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split, Shares Plunge 38.4%
- Reverse Stock Split Announcement: Aptevo Therapeutics has announced a 1-for-18 reverse stock split effective December 29, converting every 18 shares into one, which has led to a significant 38.4% drop in share price to $0.57, indicating a negative market reaction despite prior shareholder approval in July.
- Severe Market Reaction: Following the reverse stock split announcement, Aptevo's shares plummeted sharply during Friday's session, reflecting investor concerns about the company's future prospects, which could adversely affect its financing capabilities and market confidence.
- Shareholder Approval Context: The final ratio for the reverse split was approved by the board in mid-December, despite having received shareholder support at the July annual meeting, yet the market's response raises questions about the company's governance and strategic direction.
- Industry Impact: The sharp decline in Aptevo's stock price may affect its competitive position in the biopharmaceutical sector, particularly regarding financing and partnership opportunities, as investors may reassess its investment value.
See More
Galecto Grants 312,535 Stock Options to New Employee
- Stock Option Grant: On December 15, 2025, Galecto's Board approved the grant of 312,535 non-qualified stock options to a new employee at an exercise price of $32.00 per share, aimed at attracting talent and enhancing the company's competitive edge.
- Incentive Plan: The grant follows the company's 2022 Inducement Plan, with options vesting 25% on the first anniversary and subsequently 1/48th monthly, ensuring employee retention to achieve long-term objectives.
- Talent Attraction: By offering attractive stock options, Galecto aims to attract and retain key talent to support its innovative R&D in hematological cancer treatments, thereby strengthening its market position in the biotechnology sector.
- Future Outlook: Galecto plans to submit an IND application for its lead asset DMR-001 in mid-2026, with the new employee's addition expected to accelerate the R&D process and drive breakthroughs in antibody therapies.
See More
Galecto Grants 312,535 Stock Options to New Employee
- Stock Option Grant: On December 15, 2025, Galecto's Board approved the grant of 312,535 non-qualified stock options to a new employee at an exercise price of $32.00 per share, aimed at attracting talent and enhancing the company's competitive edge.
- Incentive Plan: The grant is made under the Company's 2022 Inducement Plan, with options vesting 25% on the first anniversary and 1/48th monthly thereafter, ensuring the employee's continued employment to earn the options.
- Talent Attraction: By offering attractive stock options, Galecto aims to draw key talent to support its clinical development in hematological cancer treatments, thereby strengthening its market position in the biotechnology sector.
- Future Outlook: Galecto expects to submit an IND application for its lead asset DMR-001 in mid-2026, further advancing its antibody therapeutic pipeline and enhancing the company's innovative capabilities in treating blood cancers.
See More
Guggenheim Begins Coverage of Galecto with a Buy Rating and Sets Price Target at $32
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Stories: The platform provides unique stories generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing insights and strategies.
Market Winning Tools: Benzinga Pro equips traders with tools and information to improve their chances of success in the stock market.
See More
Galecto Prices Public Offering at $19.00 per Share, Expected to Raise $275M
- Public Offering Pricing: Galecto has priced its underwritten public offering at $19.00 per share for approximately 14.47 million shares, expecting to raise about $275 million, which will support its R&D and operations, although the stock traded 3.8% lower in after-hours trading, indicating investor caution regarding the offering.
- Underwriters' Option: The underwriters have a 30-day option to purchase an additional 2.17 million shares, providing flexibility that could enhance the company's financial position and strengthen its competitive edge in the biopharmaceutical sector.
- Offering Closure Date: The offering is expected to close on or about February 12, 2026, allowing the company ample time to optimize its funding allocation plans to ensure effective use of the proceeds and smooth project advancement.
- Executive Appointments: Galecto has appointed former Blueprint Medicines executives as COO and CMO, which may bring new strategic insights and management experience to the company, further driving its business development.
See More
Galecto Appoints New Executives to Advance DMR-001 Clinical Trials
- Executive Appointments: Galecto has appointed Sherwin Sattarzadeh as COO and Becker Hewes as CMO, both from Blueprint Medicines, leveraging their 20+ years of drug development experience to drive DMR-001 into clinical trials.
- Clinical Advancement: DMR-001, a monoclonal antibody targeting mutant calreticulin, is on track for IND submission in mid-2026, with plans for first-in-human dosing via subcutaneous administration, marking a significant step in blood cancer treatment.
- Financial Position: The company's cash balance, including $285 million raised in a PIPE in November 2025, provides a financial runway into 2029 to support multiple data milestones, including Phase 1 clinical proof-of-concept data for DMR-001 expected in 2027.
- Incentive Plan: The appointments of Sattarzadeh and Hewes come with stock incentive grants of 190,376 and 264,629 restricted stock units respectively, reflecting the company's commitment to its executive team and confidence in future growth.
See More
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split, Shares Plunge 38.4%
- Reverse Stock Split Announcement: Aptevo Therapeutics has announced a 1-for-18 reverse stock split effective December 29, converting every 18 shares into one, which has led to a significant 38.4% drop in share price to $0.57, indicating a negative market reaction despite prior shareholder approval in July.
- Severe Market Reaction: Following the reverse stock split announcement, Aptevo's shares plummeted sharply during Friday's session, reflecting investor concerns about the company's future prospects, which could adversely affect its financing capabilities and market confidence.
- Shareholder Approval Context: The final ratio for the reverse split was approved by the board in mid-December, despite having received shareholder support at the July annual meeting, yet the market's response raises questions about the company's governance and strategic direction.
- Industry Impact: The sharp decline in Aptevo's stock price may affect its competitive position in the biopharmaceutical sector, particularly regarding financing and partnership opportunities, as investors may reassess its investment value.
See More
Galecto Grants 312,535 Stock Options to New Employee
- Stock Option Grant: On December 15, 2025, Galecto's Board approved the grant of 312,535 non-qualified stock options to a new employee at an exercise price of $32.00 per share, aimed at attracting talent and enhancing the company's competitive edge.
- Incentive Plan: The grant follows the company's 2022 Inducement Plan, with options vesting 25% on the first anniversary and subsequently 1/48th monthly, ensuring employee retention to achieve long-term objectives.
- Talent Attraction: By offering attractive stock options, Galecto aims to attract and retain key talent to support its innovative R&D in hematological cancer treatments, thereby strengthening its market position in the biotechnology sector.
- Future Outlook: Galecto plans to submit an IND application for its lead asset DMR-001 in mid-2026, with the new employee's addition expected to accelerate the R&D process and drive breakthroughs in antibody therapies.
See More
Galecto Grants 312,535 Stock Options to New Employee
- Stock Option Grant: On December 15, 2025, Galecto's Board approved the grant of 312,535 non-qualified stock options to a new employee at an exercise price of $32.00 per share, aimed at attracting talent and enhancing the company's competitive edge.
- Incentive Plan: The grant is made under the Company's 2022 Inducement Plan, with options vesting 25% on the first anniversary and 1/48th monthly thereafter, ensuring the employee's continued employment to earn the options.
- Talent Attraction: By offering attractive stock options, Galecto aims to draw key talent to support its clinical development in hematological cancer treatments, thereby strengthening its market position in the biotechnology sector.
- Future Outlook: Galecto expects to submit an IND application for its lead asset DMR-001 in mid-2026, further advancing its antibody therapeutic pipeline and enhancing the company's innovative capabilities in treating blood cancers.
See More
Guggenheim Begins Coverage of Galecto with a Buy Rating and Sets Price Target at $32
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Stories: The platform provides unique stories generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing insights and strategies.
Market Winning Tools: Benzinga Pro equips traders with tools and information to improve their chances of success in the stock market.
See More
